Chemoradiotherapy improves survival after pancreatic adenocarcinoma resection
the ONA take:
Chemoradiotherapy was independently associated with improved overall survival after the resection of pancreatic adenocarcinoma, particularly among patients with R1 resection and pN1 disease, according to results from a large national cohort study published online ahead of print in the journal Cancer.
For the study, researchers sought to compare the effectiveness of chemotherapy with chemoradiotherapy in patients with pT1-3N0-1M0 pancreatic adenocarcinoma after pancreatectomy. Researchers identified 6,165 patients from the National Cancer Data Base who were treated with chemotherapy with or without radiotherapy.
Results showed that chemoradiotherapy was associated with improved overall survival vs chemotherapy alone. Subgroup analyses demonstrated that chemoradiotherapy was significantly associated with improved overall survival among those with pT3 or pN1 disease and both R0 resection and R1 resection.
The findings suggest that a prospective randomized head-to-head trial comparing adjuvant chemotherapy with chemoradiotherapy are warranted to assess their efficacy in patients with pancreatic adenocarcinoma who have undergone pancreatectomy.
Chemoradiotherapy was independently associated with improved overall survival after the resection of pancreatic adenocarcinoma.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|